Sumary of Don’t use remdesivir in hospitalized coronavirus patients, WHO panel advises:
- Gilead had published results from a phase 3 ACTT-1 trial shortly before the approval that “demonstrated faster recovery times”.
- However, the WHO Solidarity Trial showed the drug had little or no effect on 28-day mortality or length of hospital stay for coronavirus patients..
- It was one of four tested in the trial with the researchers concluding “the main outcomes of mortality, initiation of ventilation and hospitalization duration were not clearly reduced by any study drug.”.
- The WHO conclusions on remdesivir are in contrast with an NIH-led study that found it to shorten patients’ path to recovery by up to four days…